FISH Carcinoma cervice uterina

 

Identificazione certa e quantizzazione delle cellule tumorali nelle displasie di basso grado mediante FISH (Fluorescence In Situ Hybridization) automatizzata


Alameda F, Espinet B, Corzo C, Muñoz R, Bellosillo B, Lloveras B, Pijuan L, Gimeno J, Salido M, Solé F, Carreras R, Serrano S, 3q26 (hTERC) gain studied by fluorescence in situ hybridization as a persistence-progression indicator in low-grade squamous intraepithelial lesion cases. Human Pathology 2009; 40: 1474-1478.


Caraway N, Khanna A, Dawlett M, Guo M, Guo N, Lin E, Katz RL, Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecologic Oncology, July 2008; 110 (1): 37-42.

 

Chen SM, Lin W, Liu X, Zhang YZ. Significance of human telomerase RNA gene amplification detection for cervical cancer screening. Asian Pac J Cancer Prev. 2012;13(5):2063-8

 

JJiang J, Wei LH, Li YL, Wu RF, Xie X, Feng YJ, Zhang G, Zhao C, Zhao Y, ZChen Z, Detection of TERC Amplification in Cervical Epithelial Cells for the Diagnosis of High-Grade Cervical Lesions and Invasive Cancer. Journal of Molecular Diagnostics, November 2010; 12, (6):808-817.


Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T, Genomic Amplification of the Human Telomerase Gene (TERC) in Pap Smears Predicts the Development of Cervical Cancer. American Journal of Pathology, April 2005; 166 (4): 1229-1238.


Jalali GR, Herzog TJ, Dziura B, Walat R, et al. Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. American Journal of Obstetrics & Gynecology 2010; 202 (6): 581.e1-581.e5.

 

Jalali GR, Herzog TJ, Dziura B, Walat R, et al. Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. American Journal of Obstetrics & Gynecology 2010; 202 (6): 581.e1-581.e5.

 

Rodolakis A, Biliatis I, Symiakaki H, Kershnar E, Kilpatrick MW, Haidopoulos D, Thomakos N, Antsaklis A. Role of chromosome 3q26 gain in predicting progression of cervical dysplasia. Int J Gynecol Cancer. 2012 Jun;22(5):742-7. doi: 10.1097/IGC.0b013e31825104bd.


Verri A, Un nuovo test per la prevenzione del tumore al collo dell’utero. CDINews agosto 2009; 15: 2.


Verri A, Jalali GR, Cecchini G, MD, Diani S, Dorji T, Kilpatrick MW, Grazioli V, Walat RJ, Significant Progression of Uterine Cervical Epithelial Lesion Accompanied by Marked Increase in 3q26 Gene Amplification. Labmedicine March 2011; 42 (3): 134-136. 1

FISH Carcinoma uroteliale

 

Dorji T, Grazioli V. Identificazione sicura delle cellule tumorali di origine uroteliale mediante FISH automatizzata.


Halling KC, Kipp BR. Bladder Cancer Detection Using FISH (UroVysion Assay). Adv Anat Pathol. 2008; 15 (5):279-286.


Kipp BR, Tanasescu M, Else TA, Bryant SC, Karnes RJ, Sebo TJ, Halling KC. Quantitative Fluorescence in Situ Hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. Journal of Molecular Diagnostic 2009; 11(2):148-154.


Verri A, Sensibilità ed automazione nella diagnosi e nel monitoraggio della neoplasia vescicale. CDINews Aprile 2009; 14:5


Ding T, Wang YK, Cao YH, and Yang LY, Clinical Utility of Fluorescence In Situ Hybridization for Prediction of Residual Tumor After Transurethral Resection of Bladder Urothelial Carcinoma. Urology 2011; 77:855-859.


Mengual L, Aguilera M, Ribal MJ, Burset M, Villavicencio H, Oliver A, Alcaraz A, Clinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Gue´rin Therapy. European Urology 2007; 52 :752–759. Urology 2011; 77:855-860.

 

FISH Adenocarcinoma polmonare

 

Kwak EL, Bang YJ, Camidge DR, et al. Kinase inhibition in non-small-cell lung cancer. Anaplastic lymphoma. N Engl J Med. 2010;363(18):1693-1703.


Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Non-Small Cell Lung Cancer (Version 3.2011). © 2011 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Accessed [March 28, 2011].

FISH Carcinoma della mammella e adenocarcinoma gastrico

 

Eroglu Z, Tagawa T, Somlo G. Human Epidermal Growth Factor Receptor (HER) Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer. Oncologist. 2014 Jan 16. [Epub ahead of print].


He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol. 2013;19(14):2171-8. doi: 10.3748/wjg.v19.i14.2171.


Tolaney S. New HER2-Positive Targeting Agents in Clinical Practice. Curr Oncol Rep. 2014 Jan;16(1):359. doi: 10.1007/s11912-013-0359-8.


FISH Tumore del cavo orale

 

S. Gabba, E. Giannini, L. Borghi, G. Fellegara, C. Marcialis, M. Grugni, MP. Foschini, E. Repetti, T. Dorji, V. Grazioli. Valutazione del guadagno di hTERC (3q26) attraverso la tecnica FISH per predire l’evolversi delle lesioni precoci del cavo orale. European Cancer Congress 2013, ECCO17, ESMO38, ESTRO32 "Reinforcing multidisciplinarity". Amsterdam, 27 Settembre-1 ottobre 2013.



SCOPRI DOVE SIAMO

21 sedi in tutta Milano e Provincia

Via Saint Bon Simone, 20, 20147 Milan, Italy Sede centrale

PER PRENOTAZIONI O INFORMAZIONI

  • telefono

    • Privati e Fondi 02.48317444
    • SSN 02.48317555